Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock Position Lowered by Comerica Bank

Comerica Bank lowered its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,460 shares of the life sciences company’s stock after selling 6,317 shares during the period. Comerica Bank owned approximately 0.10% of Integra LifeSciences worth $1,802,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank purchased a new position in Integra LifeSciences during the 4th quarter valued at about $8,967,000. Principal Financial Group Inc. lifted its position in Integra LifeSciences by 5.5% in the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock worth $9,603,000 after buying an additional 22,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after buying an additional 913 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Integra LifeSciences by 33.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock worth $448,000 after acquiring an additional 4,967 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IART. JMP Securities cut their price target on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research note on Friday. JPMorgan Chase & Co. reduced their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday. Wells Fargo & Company dropped their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Truist Financial reduced their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Finally, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Four analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average target price of $18.63.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $12.25 on Friday. Integra LifeSciences Holdings Co. has a 12 month low of $11.60 and a 12 month high of $32.66. The company has a market cap of $946.31 million, a P/E ratio of -136.10, a P/E/G ratio of 0.73 and a beta of 1.27. The business’s 50 day moving average is $18.93 and its two-hundred day moving average is $21.87. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.